International Phase III Randomised Study to Evaluate the Efficacy of Maintenance Therapy With Olaparib and Cediranib or Olaparib Alone in Patients With Relapsed Ovarian Cancer Following a Response to Platinum-based Chemotherapy
Latest Information Update: 06 Jun 2024
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ICON9
- 01 Jan 2021 Accrual is expected to be completed in 2024 and results will be presented in 2025, as per trial design published in the International Journal of Gynecological Cancer.
- 01 Jan 2021 Trial design has been published in the International Journal of Gynecological Cancer
- 03 Jan 2019 Status changed from not yet recruiting to recruiting.